Crizanlizumab

Crizanlizumab is a medication designed to treat sickle cell disease, a genetic condition that causes red blood cells to become misshapen and block blood flow. This drug works by targeting a specific protein that helps these sickle-shaped cells stick to blood vessel walls. By blocking this interaction, crizanlizumab reduces the frequency of painful crises and other complications related to the disease. It is administered through an injection and is used alongside other treatments to help improve the quality of life for individuals living with sickle cell disease.